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Available online xxxxBackground: Atrial ﬁbrillation (AF) is themost common cardiac arrhythmia, and associatedwith increased risk of
morbidity and mortality. AF surgery is widely used for rhythm control of AF, but previous studies have shown
varying results. This study sought to investigate the long-term efﬁcacy of concomitant maze IV (CMIV) surgery
in an unselected AF population and identify predictors of late AF recurrence.
Methods: In total 144 consecutive patients, who underwent CMIV between January 2006 and December 2010
were enrolled. By data from electronic medical records, registers, and rhythm prints, late AF recurrences and
heart rhythm at latest follow-upwere retrospectively registered. All patients still alive were invited to an ambu-
lant follow-up to update rhythm status.
Results: During a median (IQR) follow-up of 7.39 (2.67) years, 114 (79.2%) patients had recurrence. The cumula-
tive incidence of sinus rhythm (SR) without antiarrhythmic drugs (AADs) was 52.3% after 1 year. Long-term re-
sults after 2, 5 and 7 years were 47.9%, 32.6% and 25.1%, respectively. At latest follow-up 34.7% were in SR off
AADs. No difference in 10-year event-free survival stratiﬁed by recurrence were found (p= 0.678). Contrary,
time to death (5.40 vs. 3.43 years, p= 0.004) revealed death as competing risk event. The Fine-Gray model
identiﬁed preoperative sustained AF (SAF) (SHR 3.54, 95%CI [2.35;5.32], p b 0.001), AF duration (1.08, [1.05;1.11],
p b 0.001), and postoperative atrial tachyarrhythmia (ATA) (2.29, [1.21;4.35], p=0.011) as predictors.
Conclusion: CMIV in the present cohort provided limited long-term success in obtaining SR. SAF, longer AF dura-
tion, and postoperative ATA were associated with late AF recurrence.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Cardiac arrhythmia
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Late recurrence1. Introduction
Atrialﬁbrillation (AF) is themost common cardiac arrhythmia,more
frequently affecting men and elderly, and associated with increased
morbidity and mortality,[1,2], especially due to heart failure or stroke,
[1,3]. AFmanagement comprises oral anticoagulation for stroke preven-
tion and rate and/or rhythm control to improve symptoms and pre-
serve left ventricular function. Rhythm control modalities include
antiarrhythmic drugs (AADs), cardioversion, catheter ablation, and AF
surgery,[1].
Present evidence shows that AADs and ablation procedures, mostly
catheter-based pulmonary vein (PV) isolation, reduce rather than elim-
inate AF,[1,4,5]. Cox-maze surgery aims to create an electrical labyrinthOdense University Hospital, J.B.
dense, Denmark.
eliability and freedom from bias
. This is an open access article underof functional atrial myocardium via biatrial incisions obstructing po-
tential macro re-entry circuits to prevent ﬁbrillatory conduction. The
procedure also includes left atrial (LA) appendage exclusion for pre-
vention of thromboembolism,[6]. The lesion sets of maze IV are
performed using radiofrequency energy and/or freezing, diminishing
complications and technical complexity without reducing efﬁcacy
compared to maze III,[7]. Therefore, the use of AF surgery has expanded
during recent years,[1]. Several studies have demonstrated that maze
III/IV lesions are successful in obtaining sinus rhythm (SR),[8–13] re-
gardless of whether they were performed as a stand-alone or concomi-
tant procedure,[14–16]. However, studies investigating the efﬁcacy of
maze IV differ in terms of study design and settings leading to heteroge-
neous short- and long-term rates of freedom from AF recurrence be-
tween 47 and 94%,[8,12,17–20] and 56–91%,[9,18,21–24], respectively.
Consequently, predictors of recurrence also are inconsistent.
Therefore, the aim of this retrospective cohort study was to investi-
gate the long-term efﬁcacy of concomitant maze IV (CMIV) surgery in
an unselected population of AF patients during a long follow-up and
identify possible predictors of late AF recurrence.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study design
We retrospectively identiﬁed consecutive patients, who underwent
maze IV surgery between January 2006 and December 2010 at a tertiary
Danish university center, from the Western Denmark Heart Registry.
Patients were included, if they had AF conﬁrmed by preoperative
electrocardiogram (ECG) or long-termmonitoring,[1], AF as ablation in-
dication, and survived the ﬁrst 3 months after CMIV. Patients with
catheter-based, surgical stand-alone, or incomplete maze IV procedures
were excluded. Incompleteness was deﬁned as lacking or insufﬁcient
lesions confer surgical standards,[25].
2.2. Data acquisition
Baseline and follow-up data were obtained from health care regis-
tries, electronic medical records, and during ambulant follow-up visits
in patients still alive, when the studywas performed. Data on prior hos-
pital admissions, treatments and diagnoses were retrieved from
the Danish National Patient Registry, and perioperative data from the
Western Denmark Heart Registry. Date and cause of death during
follow-up were recorded from the Danish National Patient and Cause-
of-Death Registry. The Danish National Prescription Database provided
data on medications. Echocardiographic parameters were retrospec-
tively measured on preoperative transthoracic echocardiograms
(TTEs) by a cardiologist, blinded for other study data. All datawere inde-
pendently adjudicated by two experienced cardiologists.
2.3. Surgical procedure and postoperative management
CMIV was performed after decision by a heart team,[1]. Main proce-
dures includedmitral and aortic valve surgery (i.e. repair, replacement)
and/or coronary artery bypass grafting (CABG). All patients underwent
median sternotomy, following standard cardiopulmonary bypass
with bicaval cannulation and cardioplegic arrest. A biatrial maze IV pro-
cedure was accomplished with a left and right atriotomy enabling abla-
tion close to the mitral and tricuspid valve. Remaining lesions were
performed using a bipolar radiofrequency clamp (AtriCure Inc., USA)
and cryoprobe (Frigitronics, CCS200, USA). The right atrial lesion set
consisted of a cavo-tricuspid isthmus line connected to the superior
vena cava. After cardioplegic arrest, left atrial lesions were performed;
a circumferential PV isolation, left- and right-sided PVs separately
with a superior and inferior interconnecting line (i.e. box lesion set), a
lesion from the left upper PV to the rim of left atrial appendage and
from the right lower PV to the mitral annulus. Enclosing lines around
the coronary sinus and the tricuspid and mitral annuli were made by
cryoablation. Electrical isolation of the box lesion set was documented
by assessing exit block via bipolar pacing in all patients. LA appendage
was ligated by stapling and excised.
Early postoperative care was similar to other open-heart surgery in-
cluding continuous rhythm monitoring. Patients received prophylactic
AADs. Complications within 30 postoperative days were heart failure
(admission to heart failure clinic and initiation/intensiﬁcation of
anticongestive treatment), stroke, major bleeding (Bleeding Academic
Research Consortium type 3–5), re-operation, myocardial infarction,
renal failure requiring dialysis, and mortality. Furthermore, implanta-
tion of pacemaker or implantable cardioverter deﬁbrillator (ICD), was
documented.
Routine clinical follow-up visits occurred at 1, 3, 6 and 12 months
postoperatively. A 12 lead ECG, TTE, and 48-h Holter monitoring were
routinely performed at 1 and 3months. Between hospital visits, patients
were followed with routine ECGs by the referring physician. In case of
suspected atrial tachyarrhythmia (ATA), additional Holter monitoring
was performed. Cardioversion was recommended during a postopera-
tive 3-months blanking period.2.4. Long-term follow-up
Follow-up was deﬁned as the time from the end of the blanking
period to August 1st, 2016 or death, whichever came ﬁrst. Long-term
rhythm evaluation beyond routine follow-ups was done by available
ECGs, Holter monitorings, and/or device interrogations. A12 lead ECG
(MAC 5500, GE Healthcare, UK) and 48-h Holter monitoring (Lifecard
CF, Spacelabs Healthcare, USA) were performed to update rhythm
data in all patients attending the ambulant follow-up visit. Holter
recordings were analysed by trained staff using dedicated software
(Pathﬁnder SL, SpacelabsHealthcare, USA). All ECGs andHolter analyses
were reviewed by an experienced electrophysiologist blinded for other
study data.
2.5. Deﬁnition of arrhythmias and events
Preoperative AF duration was deﬁned from the ﬁrst date of AF
documentation to CMIV and AF subtype comprised paroxysmal (PAF)
and sustained (i.e. persistent, long-standing persistent, permanent) AF
(SAF),[1]. Deﬁnitions of remaining baseline characteristics are pre-
sented in Online Table 1. Postoperative ATA during the blanking period
was deﬁned asmonitoring-documentedAF, atrial ﬂutter, or atrial tachy-
cardia lasting ≥30 s. The primary efﬁcacy endpoint was freedom from
late AF recurrence without AADs. Recurrence of AF was deﬁned as the
ﬁrstmonitoring-documented episode of AF, atrialﬂutter, or atrial tachy-
cardia lasting ≥30 s after the blanking period,[1]. Secondary efﬁcacy
endpoints were freedom from recurrence on AADs, need of additional
arrhythmia interventions (i.e. catheter ablation, pacemaker/ICD im-
plantation), stroke, all-cause and cardiovascular mortality.
2.6. Ethics
The study was performed in accordance with the Declaration
of Helsinki II and approved by the Danish Data Protection Agency
(15/49691) and Regional Scientiﬁc Ethical Committees for Southern
Denmark (S-20150209). All patients alive gave written informed con-
sent before ambulant follow-up.
2.7. Statistical analysis
Descriptive statistics of baseline characteristics were stratiﬁed by
late recurrence. Taking the possibility of differing individual follow-up
times into account, pre-, peri-, and postoperative parameters were
evaluated in a univariate Fine-Gray proportional subdistribution hazard
analysis allowing for death during follow-up as a competing risk event
to identify predictors of recurrence. Subsequently, the effect estimates
(i.e. sub-hazard ratios (SHRs)) of the given covariates were adjusted
for age and gender,[1]. Hereafter, statistically signiﬁcant and insignif-
icant covariates deemed clinically relevant were entered into a mul-
tivariate Fine-Gray regression by forced entry. Model comparisons
were mediated by Akaike Information Criteria (AIC) and Bayesian
Information Criteria (BIC) incorporating the trade-off between ﬁt
and complexity. Because of missing echocardiographic observations
(i.e. LA diameter (LAd), LA volume indexed for body surface area
(LAvI)) to some degree, evaluation of model prediction was further
based on AIC/BIC relative to Wald's χ2 test for raw data and multi-
ple imputed. The model with the lowest AIC/BIC relative to highest
Wald's index was chosen. Precondition of independence between
the event of interest and the competing risk event was ensured by
the consecutive study inclusion mediating a homogeneous cardiac
risk group, and model assumption of proportional sub-hazards was
validated by checking insigniﬁcance of time-varying covariates.
For graphically representation, Kaplan-Meier estimates were used
to depict the event-free survival, and rates of death and stroke were
compared, separately, using Log-rank test. Implementing death as
competing risk event, cumulative incidence functions (CIFs) of late AF
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ﬁed categorical predictors. Pepe andMori test was used to compare CIFs
across subgroups.
A two-tailed p-value b0.05 was considered statistically signiﬁcant.
Analyseswere performedusing STATA14 (StataCorp LP, College Station,
USA).Table 1
Baseline characteristics.
Preoperative parameter Total, n = 144 Late AF recurrence,
Age, y 69.2 ± 8.79 70.0 ± 8.14
Male gender, n (%) 103 (71.5) 78 (68.4)
AF-disposing comorbidity, n (%)
Heart failure 31 (21.5) 26 (22.8)
Cardiac valve disease 110 (76.4) 90 (78.9)
Mitral valve insufﬁ-ciency/stenosis 61 (42.4) 46 (40.4)
Aortic valve insufﬁciency/stenosis 56 (38.9) 48 (42.1)
Ischemic heart disease 72 (50.0) 53 (46.5)
Congenital heart disease 10 (6.94) 9 (7.89)
Hypertension 90 (62.5) 73 (64.0)
Obesity 38 (26.4) 33 (28.9)
Chronic kidney disease 25 (17.4) 19 (16.7)
Chronic obstructive pulmonary disease 17 (11.8) 14 (12.3)
Hyperthyroidism 4 (2.78) 4 (3.51)
Sleep apnea 3 (2.08) 3 (2.63)
Cardiovascular risk factors, n (%)
Diabetes mellitus type 2 21 (14.6) 18 (15.8)
Hypercholesterolemia 86 (59.7) 68 (59.6)
Smoking status
Ex-smoker 77 (53.5) 61 (53.5)
Smoker 19 (13.2) 14 (12.3)
Thromboembolic event, n (%) 12 (8.33) 9 (7.89)
Catheter ablation, n (%) 6 (4.17) 5 (4.39)
Pacemaker/ICD implantation, n (%) 5 (3.47) 4 (3.51)
CHA2DS2VASc, n (%)
Score 1 12 (8.33) 9 (7.89)
Score ≥ 2 119 (82.6) 98 (86.0)
Logistic EuroSCORE, % 5.35 (6.27) 5.52 (6.09)
Intermediate risk (3–5), n (%) 46 (31.9) 37 (32.5)
High risk (≥ 6), n (%) 65 (45.1) 53 (46.5)
Echocardiographic parameters
LAd, cm 4.91 ± 0.74 4.91 ± 0.85
LAvI, mL/m2 52.1 (26.3) 53.1 (24.5)
LVEF, % 53.3 ± 8.60 53.3 ± 8.06
AF characteristics
AF subtype, n (%)
PAF 73 (50.7) 46 (40.4)
SAF 71 (49.3) 68 (59.6)
AF duration, y 0.60 (4.30) 0.82 (4.92)
Perioperative Parameter Total, n = 144 Late AF recurrence, n
Cardiac surgery, n (%) 42 (29.2) 35 (30.7)
Maze IV + Mitral valve procedure 40 (27.8) 33 (28.9)
Maze IV + Aortic valve procedure 34 (23.6) 23 (20.2)
Maze IV + CABG 26 (18.1) 21 (18.4)
Maze IV + CABG + Valve procedure 2 (1.39) 2 (1.75)
Maze IV + Congenital correction 41 (28.5) 32 (28.1)
Postoperative parameter Total, n = 144 Late AF recurrence, n =
30-day surgery complication, n (%) 49 (34.0) 39 (34.2)
Major bleeding 16 (11.1) 12 (10.5)
Re-operation 4 (2.78) 3 (2.63)
Stroke 3 (2.08) 2 (1.75)
Myocardial infarction 5 (3.47) 5 (4.39)
Renal failure requiring dialysis 13 (9.03) 10 (8.77)
Heart failure 9 (6.25) 8 (7.02)
Pacemaker/ICD implantation 9 (6.25) 8 (7.02)
Postoperative ATA, n (%) 121 (84.0) 102 (89.5)
Pre-, peri- and postoperative parameters for the total study cohort. A normally distributed continuo
a categorical variable as number (percentage). Besidesmain cardiac surgeries, other procedures
repair and excision of pathological tissue in the left atrium.
AF, atrial ﬁbrillation; ICD, implantable cardioverter deﬁbrillator; LAd, left atrial diameter; LAvI,
sustained AF; CABG, coronary artery bypass grafting; ATA, atrial tachyarrhythmia.
a Comparisons by appropriate statistical tests with a p b 0.05 considered statistically signiﬁc3. Results
3.1. Baseline characteristics
A total of 171 patients were eligible, of which 144 patients (mean
age 69.2 ± 8.79 years, 71.5% males) were included (Online Fig. 1).n = 114 (79.2) Freedom from late AF recurrence, n = 30 (20.8) P Value
66.3 ± 10.6 0.038a
25 (83.3) 0.107
5 (16.7) 0.467
20 (66.7) 0.159
15 (50.0) 0.341
8 (26.7) 0.123
19 (63.3) 0.101
1 (3.33) 0.688
17 (56.7) 0.458
5 (16.7) 0.174
6 (20.0) 0.668
3 (10.0) 1.00
0 (0) 0.580
0 (0) 1.00
3 (10.0) 0.567
18 (60.0) 0.972
0.775
16 (53.3)
5 (16.7)
3 (10.0) 0.714
1 (3.33) 1.00
1 (3.33) 1.00
0.048a
3 (10.0)
21 (70.0)
4.45 (7.88) 0.560
9 (30.0) 0.578
12 (40.0)
4.89 ± 0.72 0.894
41.0 (38.2) 0.218
53.4 ± 10.6 0.985
b0.001a
27 (90.0)
3 (10.0)
0.19 (1.11) 0.002a
= 114 (79.2) Freedom from late AF recurrence, n = 30 (20.8) P Value
7 (23.3) 0.430
7 (23.3) 0.541
11 (36.7) 0.058
5 (16.7) 0.824
0 (0) 1.00
9 (30.0) 0.835
114 (79.2) Freedom from late AF recurrence, n = 30 (20.8) P Value
10 (33.3) 0.928
4 (13.3) 0.744
1 (3.33) 1.00
1 (3.33) 0.507
0 (0) 0.584
3 (10.0) 0.734
1 (3.33) 0.685
1 (3.33) 1.00
19(63.3) 0.001a
us variable is represented asmean± SD, a non-normally distributed asmedian (IQR), and
could be performed, hereunder tricuspidal valve repair, septalmyectomy, aorta ascendens
left atrial volume index; LVEF, left ventricular ejection fraction; PAF, paroxysmal AF; SAF,
ant.
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tients with PAF and SAF were almost equal with a median duration of
7 months and only a minority had previous thromboembolic events,
although 82.6% were at high risk (CHA2DS2 VASc score ≥ 2). Most pa-
tients had valvular and/or ischemic heart disease equalingmain surgical
indications. Besides extensive cardiac morbidity, preoperative mean
left ventricular ejection fraction was only mildly depressed (53.3 ±
8.60%). Almost one third had procedural complications consistent
with the fact that nearly half of the cohort were high risk patients
(logistic EuroSCORE ≥6). Main complications were major bleeding and
renal failure, and 84.0% had a monitoring-documented ATA during the
blanking period.
3.2. Long-term follow-up
During a median follow-up of 7.39 (2.67) years, 48 patients (33.3%)
died. Cause of death was presumed cardiovascular in 56.3%. Ischemic
stroke was reported in 20 patients (13.9%), of which 30.0% were fatal.
The cumulative 10-year event-free survival was irrespective of recur-
rence for stroke (p= 0.525) and death (p= 0.678) (Online Fig. 2),
but median time to death in patients with and without recurrence dif-
fered signiﬁcantly (5.41 vs. 2.23 years, p= 0.004) underlining death
being a competing risk event.
At 3-month postoperatively, 78.5%/71.5% of the patients were in
SR on/off AADs. This prevalence was 87.5%/77.6% at 6 months and
83.2%/79.0% at 1 year. During long-term follow-up, 114 patients (79.2%)
had recurrence, of which 61.4% (n= 70) were AF and the remainingFig. 1. Cumulative incidence function of late AF recurrence for the total cohort and stratiﬁed by
cohort during follow-up. In total, 35.4% 95%CI [27.7;43.2] of the cohort had recurrence after 6 m
after 1, 2, 5 and 7 years, respectively; B. Statiﬁcation by preoperative AF subtype; C. Statiﬁcation b
by the Pepe and Mori test (PeMo). AF, atrial ﬁbrillation; CMIV, concomitant maze IV; ECG, elecatrial ﬂutter (n= 41) and atrial tachycardia (n= 3). Fig. 1A shows
the cumulative incidence of late AF recurrence for the total cohort.
Cumulative freedom from recurrence on/off AADs was 64.6%/54.9%
and 56.9%/52.3% at 6 and 12 months, and 49.3%/47.9%, 32.6%/32.6%
and 25.1%/25.1% after 2, 5 and 7 years, respectively. Along with
the high recurrence rate, a considerable proportion of the cohort
needed catheter ablation (n=12) and/or pacemaker/ICD implantation
(n= 21). Nevertheless, only 37.4%/34.7% of the patients were in SR
on/off AADs at latest follow-up with a median time to latest follow-up
of 6.99 (3.17) years. By looking at the group of patients with late AF
reccurence, it appeared that most of these patients still had an ATA
(n=81, 71.1%), of which 48.2% (n=55) were AF and the remaining
atrial ﬂutter (n=22) and atrial tachycardia (n=4).
3.3. Predictors of late AF recurrence
From the initial predictor analysis of baseline parameters deemed
clinically relevant, signiﬁcant associations were found for SAF subtype,
AF duration and postoperative ATA (Table 2). Comparable ﬁndings for
hyperthyroidism and diabetes were regarded as statistically random.
A corresponding analysis of all parameters is presented in Online
Table 2. Subsequently, these possible predictors were integrated in the
multivariate analysis along with the variable cardiac valve disease re-
quiring treatment to introduce the clinically reasoning of worsening of
cardiac function as a predictor (Table 3). SAF posed a 3.5-fold increased
risk of recurrence compared to PAF ([2.35;5.32], p b 0.001). Addition-
ally, one-year increase in AF duration (1.08 [1.05;1.11], p b 0.001) andindependent categorical predictors. A. The cumulative incidence of recurrence for the total
onths corresponding 43.1% [34.9;51.0], 50.7 [42.3;58.5], 67.4 [59.0;74.4], 74.9 [66.8;81.2]
y postoperative atrial tachyarrhythmia (ATA); Equality between subgroupswas evaluated
trocardiogram.
Table 2
Univariate predictor analysis.
Parameter Univariate analysis Adjusted† analysis
SHR [95% CI] P value SHR [95% CI] P value
Age, y 1.03 [1.01;1.06] 0.008⁎ 1.03 [1.01;1.06] 0.011⁎
Male gender 0.74 [0.51–1.09] 0.132 0.81 [0.54;1.21] 0.305
AF-disposing comorbidity
Heart failure 1.23 [0.80;1.88] 0.342 1.22 [0.76;1.96] 0.414
Cardiac valve disease 1.54 [1.00;2.37] 0.051 1.51 [0.97;2.36] 0.068
Ischemic heart disease 0.81 [0.56;1.16] 0.242 0.71 [0.48;1.05] 0.089
Congenital heart disease 1.28 [0.69;2.37] 0.441 1.72 [0.97;3.03] 0.062
Hypertension 1.20 [0.82;1.74] 0.345 1.06 [0.71;1.57] 0.774
Obesity 1.26 [0.86;1.82] 0.233 1.38 [0.94;2.03] 0.096
Chronic kidney disease 0.85 [0.52;1.37] 0.504 0.75 [0.44;1.27] 0.277
Chronic obstructive 1.13 [0.64;1.99] 0.679 0.93 [0.51;1.71] 0.827
Pulmonary disease
Hyperthyroidism 2.61 [1.21;5.65] 0.015⁎ 2.43 [1.18;5.02] 0.016⁎
Sleep apnea 1.97 [0.85;4.56] 0.114 2.11 [0.84;5.30] 0.113
Cardiovascular risk factors
Diabetes mellitus type 2 1.85 [1.05;3.27] 0.034⁎ 1.94 [1.10;3.43] 0.023⁎
Hypercholesterolemia 1.08 [0.75;1.55] 0.689 1.00 [0.68;1.47] 0.992
Smoking status 1.00 [0.78;1.30] 0.981 1.05 [0.79;1.39] 0.745
CHA2DS2VASc score 1.55 [1.15;2.11] 0.004⁎ 1.27 [0.90;1.80] 0.169
Echocardiographic
parameters
LAd, cm 1.16 [0.88;1.53] 0.294 1.22 [0.92;1.62] 0.169
LAvI, mL/m2 1.00 [0.99;1.01] 0.460 1.00 [0.99;1.01] 0.406
LVEF, % 1.00 [0.97;1.02] 0.837 1.00 [0.98;1.03] 0.989
AF characteristics
SAF subtype 3.65 [2.43;5.47] b0.001⁎ 3.63 [2.43;5.41] b0.001⁎
AF duration, y 1.08 [1.05;1.11] b0.001⁎ 1.08 [1.05;1.11] b0.001⁎
Cardiac surgery
Maze IV + CABG 0.63 [0.40;1.01] 0.057 0.64 [0.40;1.04] 0.071
Maze IV + Cardiac valve
procedure
1.51 [0.97;2.33] 0.066 1.49 [0.96;2.33] 0.076
Postoperative ATA 2.70 [1.58;4.60] b0.001⁎ 2.40 [1.40;4.11] 0.001⁎
Univariate predictor analysis of pre-, peri- and postoperative parameters deemed clinically
relevant. Parameters were evaluated in a univariate Fine-Gray model incorporating
the possibility of differing individual follow-up times and allowing for death during
follow-up as a competing risk event. Subsequently, the covariates were adjusted for age
and gender as well-known risk factors for AF.
SHR, sub-hazard ratio; CI, conﬁdence interval; other abbreviations as in Table 1.
⁎ A p b 0.05 were considered statistically signiﬁcant.
† Adjusted for age and gender.
24 C.S. Engelsgaard et al. / IJC Heart & Vasculature 19 (2018) 20–26presence of postoperative ATA (2.29 [1.21;4.35], p=0.011) were asso-
ciated with increased risk of recurrence. Neither valve disease requiring
treatment (1.37 [0.88;2.13], p=0.160), nor the addition of LA size pro-
vided further predictive information (LAd: 1.23 [0.93;1.63], p=0.141,
LAvI: 1.01 [1.00;1.02], p= 0.216). To account for missing echocardio-
graphic observations (LAd = 11.8%, LAvI = 38.2%), multiple imputed
data was implemented in the analysis showing similar insigniﬁcant
results with no improvement in model prediction (Online Table 3).Table 3
Multivariate predictor analysis.
Parameter Multivariate analysis 1 Multivariate analysis 2
SHR [95% CI] P value SHR [95% CI] P
Age, y 1.03 [1.00;1.05] 0.034⁎ 1.02 [1.00;1.05] 0
Male gender 0.73 [0.51;1.07] 0.106 0.70 [0.49;1.00] 0
Cardiac valve procedure 1.38 [0.89;2.15] 0.154 1.42 [0.90;2.24] 0
SAF subtype 3.57 [2.38;5.34] b0.001⁎ 3.69 [2.44;5.56] b
AF duration, y 1.07 [1.05;1.10] b
Postoperative ATA
Multivariate predictor analysis of pre-, peri- and postoperative parameters deemed clinically relevan
model predictionwas evaluated by comparing the estimates of AIC/BIC in analysis 1, 2 and 3 rela
LAd (1.23 [0.93;1.63], p=0.141, AIC/BIC= 808.36/828.21, Wald's test = 68.27) and LAvI (1.0
model prediction.
AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; other abbreviations as in T
⁎ A p b 0.05 were considered statistically signiﬁcant.
† The estimates of AIC/BIC and Wald's index correlated to the multivariate analysis including
‡ The basic multivariate model included age and gender.Fig. 1B–C shows the cumulative incidence of late AF recurrence strat-
iﬁed by the independent categorical predictors. Comparing CIFswith re-
gard to subtype (Fig. 1B), a signiﬁcantly higher incidence appeared in
SAF patients (p b 0.001). Already at 1-year follow-up, 66.2% [53.9;75.9]
with SAF vs. 20.5% [12.2;30.4] with PAF had recurrence. These ﬁgures
increased to N90% of the SAF patients after 5 years (91.5% [82.2;96.1]).
A similar difference in CIFs according to postoperative ATA is shown in
Fig. 1C (48.8% [39.6;57.3] vs. 13.0 [3.30;29.7] at 1-year, p b 0.001). All
time-speciﬁc CIFs are shown in Online Table 4.
4. Discussion
To the best of our knowledge, this is the ﬁrst retrospective cohort
study cumulatively evaluating the long-term efﬁcacy ofmaze IV surgery
in an unselected AF population, which is representative for clinical prac-
tice by being older and having signiﬁcant co-morbidity. We found a
relatively low short- and long-term rate of freedom from late AF recur-
rence without AADs, and at latest follow-up only approximately one
third of the cohort was in SR off AADs. Furthermore, we identiﬁed an
association between preoperative SAF, AF duration and postoperative
ATA and a higher risk of recurrence.
4.1. The long-term efﬁcacy of maze IV surgery
CMIV is recommended in current guidelines of AF management,[1]
and recently, a systematic review of eight randomized trials (RCTs)
has shown high success rates after concomitant AF surgery,[13]. How-
ever, the procedure efﬁcacy is still under debate given considerable
heterogeneity regarding several study aspects; the AF populations
investigated, extent of maze IV lesions, use of ablation technologies,
follow-up time and methodology.
When comparing the cumulative freedom from AF recurrence and
the estimated short- and long-term prevalence of SR without AADs at
certain time points in the present study, one of the reporting problems
regarding efﬁcacy of CMIVbecomes evident, in that the time-dependent
SR prevalence was higher, thus overestimating procedure efﬁcacy. A
similar tendency is seen when comparing our results with previous
studies using the prevalence of freedom from recurrence as efﬁcacy
endpoint,[12,14–18,21,24]. Five cohort studies,[12,14–17] estimated
the short-term success rate at 77–94% after 1 year with the lowest
rate found in a study of mainly SAF patients undergoing uni−/bipolar
radiofrequency energy CMIV,[17]. Gillinov et al.,[8] randomized SAF
patients to surgical ablation (49.6% biatrial CMIV) or no ablation. After
1 year, 66.0% in the CMIV-group were in SR off AADs. Other RCTs
showed similar results,[13], but with even lower success rates after
only left-sided lesions,[19].
Only a few long-term follow-up studies exist, and even fewer use cu-
mulative CMIV evaluations. The overall prevalence of SR was 56–91%Multivariate analysis 3 AIC/BIC† Wald's χ2 test†
value SHR [95% CI] P value
.091 1.02 [0.99;1.05] 0.170
.047⁎ 0.74 [0.52;1.06] 0.102 985.73/991.67‡ 7.75‡
.128 1.37 [0.88;2.13] 0.160 984.38/993.29 11.36
0.001⁎ 3.54 [2.35;5.32] b0.001⁎ 946.74/958.62 51.46
0.001⁎ 1.08 [1.05;1.11] b0.001⁎ 924.30/939.11 75.87
2.29 [1.21;4.35] 0.011⁎ 917.98/935.76 86.44
t. Parameters were evaluated in a confounder-adjusted Fine-Graymodel. Improvement of
tive toWald's χ2 test with last-mentioned having the best predictive effect. The addition of
1 [1.00;1.02], p=0.216, AIC/BIC= 508.06/525.40, Wald's test = 80.19) did not improve
ables 1 and 2.
the following parameter in the given table row and the preceding parameters.
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tients off AADs,[18,21,23,24]. Studies either including PAF/SAF patients
equally and using bipolar radiofrequency energy,[18,24] or excluding
all patients with incomplete 5-year follow-up data,[21] found the
highest prevalence. The discrepancy to our results additionally indicates
that success rates may be largely overestimated when excluding the
deceased patients. Two cohort studies cumulatively estimated the inci-
dence of recurrence without reporting AAD treatment in SAF patients
undergoing CMIV (52.7%) or no ablation,[22] and PAF/SAF patients
receiving left-sided CMIV,[20]. Freedom from recurrence was 75.4%
and 65.4–68.9% after 2 and 5 years, respectively. Although performing
cumulative procedure evaluation, the success rates reported in these
studies may still be overestimated due to lacking competing risk imple-
mentation, especially when taking into account that both studies in-
cluded elderly, multi-morbid patients, of which more than half were
females with higher risk of death. Competing risk models were only
used in two recent studies,[9,23]. Gelsomino et al.,[23] retrospectively
investigated SAF patients undergoing bipolar radiofrequency energy
CMIV (45.8% biatrial). Maintenance of SR on/off AADs after 7 years
was 26.5%/15.3%. On the contrary, a multicenter study,[9] found a high
8-year freedom from AF off AADs (60%) in SAF-patients. The highest
success rate occurredwhen performing biatrial lesions by bipolar radio-
frequency energy. Compared to our cohort, the diverging long-term
success rates in the two studies might be due to a different 30 days
and 6 months blanking period, respectively, not in line with current
guidelines, and the fact that approximately one third of recurrences in
our study occurred between 3 and 6 months postoperatively,[1]. Addi-
tionally, the extremely low long-term success in Gelsomino et al.,[23]
might be due to the lack of right atrial lesions stated crucial especially
in SAF patients,[9,23,26–28].
Moreover, it is unclear, whether CMIV prevents stroke and reduces
all-cause mortality. Although, AF is independently associated with in-
creased risk of stroke and death,[1], SR maintenance using different
rhythm control strategies, hereunder CMIV, has not shown prognostic
beneﬁt,[1,8,13,21,24,26]. This is in line with this study, where the
annual incidence of stroke and death corresponded with the average
rates for AF patients on anticoagulants,[1]. Whether stroke prevention
in CMIV-patients is related to ongoing anticoagulation or LA appendage
exclusion remains uncertain, and we neither investigated this.
4.2. Predictors of late AF recurrence
The extent of atrial remodelling facilitating AF triggering ectopic ac-
tivity and re-entry circuitsmay be clinically reﬂected by the SAF subtype
as being a strong predictor of recurrence in our cohort. Even though we
were unable to group SAF in persistent or permanent, previous studies
have underlined the critical distinction between PAF and non-PAF,
[1,18,19,24,29]. The lower risk of recurrence in PAF patients could also
be a result of insufﬁcient detection, which might partly explain the
delay in time to recurrence in our subgroup. On the other hand, a ten-
dency toward greater need of biatrial lesions in SAF patients is fre-
quently stated,[9,10,23,28] reﬂecting a more extensive remodelling,
and, thus, a higher risk of recurrence.
We also found a longer AF duration strongly associated with late
recurrence, but to a minor degree than for SAF subtype. This may be
explained by our deﬁnition of duration, which might not correspond
to the real time in AF. Our study was neither powered to investigate
duration categorically, where previous studies mainly including SAF
patients found a higher risk of recurrence when doing so,[20,23]. This
may indicate a tendency toward irreversible remodelling limiting
CMIV efﬁcacy in these patients.
Contrary to our clinical hypothesis, patients undergoing valve
surgery did not have a higher risk of recurrence, even though severe
cardiac valve disease should be highly proarrhythmic. Our study
was not yet powered to show a predictive effect of LA dilatation as ex-
pected from previous results,[9,15,17,18,21–24]. While the associationappeared continuous in these studies, a review including 12 observa-
tional studies demonstrated a higher predictive power of LAd/LAvI
N6.0 cm/135 mL/m2,[30]. In our study, the proportion of patients with
this LA size was limited. Our insigniﬁcant ﬁndings may also be related
to the limited preoperative TTE data varying in quality, especially
regarding atrial dimensions and function.
Comparablewith previousﬁndings,[10,15,24],we found the presence
of postoperative ATA additionally predictive. Some studies have ex-
plained the high incidence of ATAs after cardiac surgery by propagated
atrial remodelling together with an ablation-mediated increase inmyo-
cardial inﬂammatory response,[15,31]. The high 8-year success rate
demonstrated in the multicenter study,[9] using a 6 months blanking
period, possibly suggests that an aggressive rhythm control strategy
during short-term follow-up can improve long-term success, why a
strict protocol of post-CMIV management seems mandatory.
4.3. Study limitations
The present study has several limitations. Firstly, the observational
and retrospective single-centre design together with the limited num-
ber of patients allow no deﬁnite conclusion regarding procedure efﬁ-
cacy. However, the extended data collection through combination
of data sources might facilitate more precise results. We cannot pre-
clude selection bias due to the exclusion of patients, who postopera-
tively died during the ﬁrst 3 months. However, in-hospital mortality
was not related to the maze procedure, and the consecutive study en-
rollment may have ensured a homogeneous cardiac risk group with
comparable baseline characteristics. We excluded these patients
to counterbalance bias elimination in statistical models, because they
were not at risk of recurrence. Secondly, success rates may be affected
by procedural factors, as CMIV was performed by six expert surgeons,
not all lesions were tested for transmurality, and cryoablation was
used for enclosing lines. Thirdly, even though the ECG-/Holter
monitoring-based follow-up may have improved hospital attendance,
optimal rhythm evaluation would rather be continuous monitoring,
as we might have missed asymptomatic and paroxysmal ATA episodes.
Though, this might not have been critical because of the high recur-
rence rate.
4.4. Conclusions
The present study shows, that CMIV with complete transmurality of
the box lesion set appears to provide limited long-term success in terms
of obtaining SR, especially in patients with a longer history of sustained
AF, suggesting an association between the extent of atrial remodelling
and procedure efﬁcacy. Presence of postoperative ATA is also indepen-
dently associated with late AF recurrence. Consequently, a careful
evaluation of preoperative AF characteristics and a strict protocol of
post-CMIV management may be substantial for increasing the applica-
bility of CMIV. High-quality RCTs are necessary to conﬁrm our ﬁndings
and elucidate the evidence of the procedure potential in modern AF
treatment.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcha.2018.03.009.
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